PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference

PETAH TIKVA, Israel, Sept. 20, 2021 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD ), a phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX technology, today announced its participation in the Cantor